Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma

doi:10.5306/wjco.v12.i12.1215

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4633)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

472

WORD

183

HTML

1535

Figures (1-3)

211

Tables (1-2)

218

Sum=2619

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

311

Download

556

Sum=867

Publishing Process of This Article

Item

Count

Browse

407

Download

740

Sum=1147

Dec 24, 2021 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Oncol. Dec 24, 2021; 12(12): 1215-1226
Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1215

Table 2 Changes in circulating tumor DNA content during radiotherapy for locally advanced rectal cancer

Patient ID	Mutation	Baseline mutated ctDNA	ctDNA analysis	-1 h	0	1 h	3 h	6 h	12 h	24 h	36 h	48 h	72 h	96 h	Radiation dose per day / number of fractions / total dose accumulated for the blood collection time
ArAS	KRAS G12S	Neg	C (mut)¹	0	0	0	3	0	0	0	0	14	12	nd	2.0 Gy/4 fr/8 Gy + capecitabine³
			C (mut + wt)²	642	1006	1337	1963	633	906	829	762	4298	3088	nd
			VAF, %	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	nd
GaZM	KRAS G13D	Neg	C (mut)	0	0	0	26	37	59	40	50	46	5	80	2.0 Gy/5 fr/10 Gy + capecitabine³
			C (mut + wt)	6	7	8	866	808	1450	604	441	506	112	1219
			VAF, %	0.0	0.0	0.0	3.0	4.6	4.1	6.6	11.3	9.1	4.5	6.6
DaKS	KRAS G12A	Pos	C(mut)	22	22	52	134	42	33	32	102	27	65	36	5.0 Gy/5fr/25 Gy
			C (mut + wt)	295	118	655	1802	588	292	170	549	359	391	331
			VAF, %	7.5	18.6	7.9	7.4	7.1	11.3	18.8	18.6	7.5	16.6	10.9
ArTP	KRAS Q61L	Pos	C (mut)	39	0	0	26	10	0	39	nd	42	107	nd	2.0 Gy/4 fr/8 Gy
			C (mut + wt)	7606	9430	4036	5028	3187	3033	12574	nd	10622	14443	nd
			VAF, %	0.5	0.0	0.0	0.5	0.3	0.0	0.3	nd	0.4	0.7	nd
MaLI	NRAS G12D	Pos	C (mut)	23	15	0	0	0	5	13	15	10	21	15	5.0 Gy/5 fr/25 Gy
			C (mut + wt)	981	1011	1073	1303	1309	1160	1010	724	815	673	1088
			VAF, %	2.3	1.5	0.0	0.0	0.0	0.0	1.3	2.1	1.2	3.1	1.4
MaNK	KRAS G12D	Pos	C (mut)	244	257	nd	nd	nd	Nd	254	335	415	418	387	2.0 Gy/5 fr/10 Gy + capecitabine³
			C (mut + wt)	897	1091	nd	nd	nd	Nd	1424	1832	2241	1719	1955
			VAF, %	27.2	23.6	nd	nd	nd	Nd	17.8	18.0	18.5	24.3	19.8
ZuNM	BRAF V600E	Neg	C (mut)	0	0	0	0	0	0	0	0	0	0	0	2.0 Gy/5 fr/10 Gy + capecitabine³
			C (mut + wt)	1652	372	522	522	522	522	671	837	1004	791	2805
			VAF, %	0	0	0	0	0	0	0	0	0	0	0
MiMF	NRAS G12D	Neg	C (mut)	0	0	0	0	0	0	0	0	0	0	0	5.0 Gy/5 fr/25 Gy
			C (mut + wt)	594	500	740	2294	804	681	681	386	644	2891	1536
			VAF, %	0	0	0	0	0	0	0	0	0	0	0
SaVV	NRAS Q61R	Neg	C (mut)	0	0	0	0	0	0	0	0	0	0	0	2.0 Gy/5 fr/10 Gy + capecitabine³
			C (mut + wt)	196	237	541	840	621	748	353	372	272	261	249
			VAF, %	0	0	0	0	0	0	0	0	0	0	0

¹C (mut): Number of mutated copies per 1 mL of plasma measured by droplet digital PCR.

²C (mut + wt): Total number of target fragment (both wt and mut) copies per 1 mL of plasma measured by droplet digital PCR.

³Capecitabine 825 mg/m² twice daily was delivered on the 1-5 d of RT.

ctDNA: Circulating tumor DNA; VAF: Variant allele frequency.

Citation: Kuligina E, Moiseyenko F, Belukhin S, Stepanova E, Zakharova M, Chernobrivtseva V, Aliev I, Sharabura T, Moiseyenko V, Aleksakhina S, Laidus T, Martianov A, Kholmatov M, Whitehead A, Yanus G, Imyanitov E. Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma. World J Clin Oncol 2021; 12(12): 1215-1226
URL: https://www.wjgnet.com/2218-4333/full/v12/i12/1215.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i12.1215